Stage IIIC Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 1 Trials for Onalespib (DB06306)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02097225Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTreatment